Hilary F Armstrong1, David Lederer2, Gina S Lovasi3, Grant Hiura4, Corey E Ventetuolo5, RGraham Barr6. 1. Columbia University Medical Center, New York, USA. Electronic address: hilary.armstrong86@gmail.com. 2. Columbia University Medical Center, New York, USA. Electronic address: davidlederer@gmail.com. 3. Drexel Dornsife School of Public Health, Philadelphia, USA. Electronic address: gsl45@drexel.edu. 4. Columbia University Medical Center, New York, USA. Electronic address: ghiura@luc.edu. 5. Brown University, Providence, USA. Electronic address: Corey_Ventetuolo@brown.edu. 6. Columbia University Medical Center, New York, USA. Electronic address: rgb9@cumc.columbia.edu.
Abstract
OBJECTIVE: Depression in patients with Chronic Obstructive Pulmonary Disease (COPD) has been shown to be chronic and potentially increase the burden of symptoms. Selective serotonin reuptake inhibitors (SSRIs) have anti-inflammatory and serotonergic effects that may improve lung function. We hypothesized that participants taking SSRIs have better lung function than those not taking SSRIs. The dataset was the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Use of SSRIs was assessed by medication inventory; spirometry was conducted following standard guidelines; dyspnea ratings were self-reported. RESULTS: Contrary to our hypothesis, FEV1 was lower, and odds of dyspnea were higher among participants taking SSRIs as compared with those not taking an antidepressant; these differences persisted even with control for potential confounders including depressive symptoms. We found no evidence of a beneficial association between SSRI use and lung function or dyspnea in a large US-based cohort.
OBJECTIVE: Depression in patients with Chronic Obstructive Pulmonary Disease (COPD) has been shown to be chronic and potentially increase the burden of symptoms. Selective serotonin reuptake inhibitors (SSRIs) have anti-inflammatory and serotonergic effects that may improve lung function. We hypothesized that participants taking SSRIs have better lung function than those not taking SSRIs. The dataset was the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Use of SSRIs was assessed by medication inventory; spirometry was conducted following standard guidelines; dyspnea ratings were self-reported. RESULTS: Contrary to our hypothesis, FEV1 was lower, and odds of dyspnea were higher among participants taking SSRIs as compared with those not taking an antidepressant; these differences persisted even with control for potential confounders including depressive symptoms. We found no evidence of a beneficial association between SSRI use and lung function or dyspnea in a large US-based cohort.
Authors: J Wanger; J L Clausen; A Coates; O F Pedersen; V Brusasco; F Burgos; R Casaburi; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D Johnson; N Macintyre; R McKay; M R Miller; D Navajas; R Pellegrino; G Viegi Journal: Eur Respir J Date: 2005-09 Impact factor: 16.671
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: E Sherwood Brown; Luis Vigil; David A Khan; Joshua D M Liggin; Thomas J Carmody; A John Rush Journal: Biol Psychiatry Date: 2005-07-05 Impact factor: 13.382
Authors: Janet Maurer; Venkata Rebbapragada; Soo Borson; Roger Goldstein; Mark E Kunik; Abebaw M Yohannes; Nicola A Hanania Journal: Chest Date: 2008-10 Impact factor: 9.410
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Abebaw M Yohannes; Hana Müllerová; Nicola A Hanania; Kim Lavoie; Ruth Tal-Singer; Jorgen Vestbo; Steven I Rennard; Emil F M Wouters Journal: Chest Date: 2016-01-05 Impact factor: 9.410